Novartis Not Expected to Renew ISS Contract
ISS is not expecting an extension to its DKK 2.0 billion (£266.2 million) integrated facility services contract with global pharmaceutical company, Novartis.
First awarded in 2012, the contract which relates to 22 production, distribution and administrative sites in four countries, expires on 31 December 2019.
In 2018 the contract generated 2.8 per cent of the Danish integrated facility service provider’s global revenues.
ISS forecasts any potential impact to be marginal at between 0.1 and 0.2 per cent of its total operating revenues during the first 12 months.